Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Monday, up 3.38% from the previous trading day, before settling in for the closing price of $27.37. Over the past 52 weeks, BEAM has traded in a range of $20.84-$49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 43297.50% over the last five years. While this was happening, its average annual earnings per share was recorded -174.30%. With a float of $72.66 million, this company’s outstanding shares have now reached $82.56 million.
The firm has a total of 436 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 12.25%, while institutional ownership is 81.92%. The most recent insider transaction that took place on Nov 06 ’24, was worth 1,347,050. In this transaction President of this company sold 51,110 shares at a rate of $26.36, taking the stock ownership to the 109,150 shares. Before that another transaction happened on Oct 14 ’24, when Company’s President sold 51,110 for $26.27, making the entire transaction worth $1,342,752. This insider now owns 160,260 shares in total.
Beam Therapeutics Inc (BEAM) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 1.73 earnings per share (EPS), higher than consensus estimate (set at -0.71) by 2.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -174.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.81 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Analysing the last 5-days average volume posted by the [Beam Therapeutics Inc, BEAM], we can find that recorded value of 0.84 million was lower than the volume posted last year of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 92.20%. Additionally, its Average True Range was 1.78.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 55.27%, which indicates a significant decrease from 68.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.83% in the past 14 days, which was higher than the 68.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.65, while its 200-day Moving Average is $26.64. Now, the first resistance to watch is $28.95. This is followed by the second major resistance level at $29.60. The third major resistance level sits at $30.58. If the price goes on to break the first support level at $27.32, it is likely to go to the next support level at $26.35. Now, if the price goes above the second support level, the third support stands at $25.69.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 2.36 billion has total of 82,806K Shares Outstanding. Its annual sales at the moment are 377,710 K in contrast with the sum of -132,530 K annual income. Company’s last quarter sales were recorded 14,270 K and last quarter income was -96,670 K.